These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 8438380)

  • 21. Prolongation of heart xenograft survival after liver hemoperfusion.
    Amorosa L; Gugenheim J; Saint-Paul MC; Benzaken S; Mouiel J
    Transplant Proc; 1990 Aug; 22(4):2002-3. PubMed ID: 2389509
    [No Abstract]   [Full Text] [Related]  

  • 22. Normal human polyclonal immunoglobulins for intravenous use significantly delay hyperacute xenograft rejection.
    Latremouille C; Haeffner-Cavaillon N; Goussef N; Mandet C; Hinglais N; Bruneval P; Bariety J; Carpentier A; Glotz D
    Transplant Proc; 1994 Jun; 26(3):1285. PubMed ID: 8029910
    [No Abstract]   [Full Text] [Related]  

  • 23. Prevention of hyperacute xenograft rejection by intravenous immunoglobulin.
    Magee JC; Collins BH; Harland RC; Bollinger RR; Frank MM; Platt JL
    Transplant Proc; 1995 Feb; 27(1):271. PubMed ID: 7878999
    [No Abstract]   [Full Text] [Related]  

  • 24. Delayed xenograft rejection in complement-depleted T-cell-deficient rat recipients of guinea pig cardiac grafts.
    Candinas D; Bach FH; Hancock WW
    Transplant Proc; 1996 Apr; 28(2):678. PubMed ID: 8623340
    [No Abstract]   [Full Text] [Related]  

  • 25. The impact of xenograft rejection on future grafting.
    Gannedahl G; Tufveson G
    Transplant Proc; 1992 Feb; 24(1):276-8. PubMed ID: 1539281
    [No Abstract]   [Full Text] [Related]  

  • 26. When does hyperacute rejection against xenohearts from newborn pigs develop in infantile monkeys?
    Lee MC; Kawauchi M; Nakajima J; Takeda M; Ono M; Oka T; Takamoto S
    Transplant Proc; 1998 Nov; 30(7):3824-5. PubMed ID: 9838674
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of soluble complement receptor type 1 on natural antibody levels during xenograft rejection.
    Pruitt SK; Baldwin WM; Marsh HC; Lin SS; Yeh CG; Bollinger RR
    Transplant Proc; 1992 Apr; 24(2):477-8. PubMed ID: 1566394
    [No Abstract]   [Full Text] [Related]  

  • 28. Structural analysis of hyperacute rejection in cardiac xenotransplantation: comparison of two different donor-recipient species combinations.
    Miyazaki K; Watanabe S; Miyatake T; Watanabe T; Kubota S; Murashita T; Abe K; Yasuda K
    Transplant Proc; 2000 Aug; 32(5):946. PubMed ID: 10936288
    [No Abstract]   [Full Text] [Related]  

  • 29. The histopathologic appearance of rejected xenografts in a neovascularized and primarily vascularized rodent system.
    Fischel RJ; King NJ; Manivel C; Almond SP; Chen S; Bolman RM; Matas AJ
    Transplant Proc; 1992 Apr; 24(2):631. PubMed ID: 1373545
    [No Abstract]   [Full Text] [Related]  

  • 30. Pathogenesis and pathology of delayed xenograft rejection in pig-to-rhesus monkey cardiac transplantation.
    Chen D; Cao R; Guo H; Chen G; Wang X; Shen S; Chen S
    Transplant Proc; 2004 Oct; 36(8):2480-2. PubMed ID: 15561288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of natural antibody synthesis by cyclophosphamide or 15-deoxyspergualin fails to prevent xenograft rejection in the guinea pig-to-rat model.
    Leventhal JR; Platt JL; Flores HC; Gruber SA; Matas AJ; Bolman RM
    Transplant Proc; 1992 Apr; 24(2):551. PubMed ID: 1566426
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of recipient strain variation on cardiac xenograft survival.
    Araneda D; DeMasi R; McFadden T; Thomas F
    Transplant Proc; 1992 Apr; 24(2):633-4. PubMed ID: 1566459
    [No Abstract]   [Full Text] [Related]  

  • 33. Complement-fixing elicited antibodies are a major component in the pathogenesis of xenograft rejection.
    Miyatake T; Sato K; Takigami K; Koyamada N; Hancock WW; Bazin H; Latinne D; Bach FH; Soares MP
    J Immunol; 1998 Apr; 160(8):4114-23. PubMed ID: 9558123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative efficacy of immunosuppressive drugs in xenografting.
    Thomas FT; DeMasi RJ; Araneda D; Marchman W; Alqaisi M; Larkin EW; Condie RM; Carobbi A; Thomas JM
    Transplant Proc; 1990 Jun; 22(3):1083-5. PubMed ID: 1693452
    [No Abstract]   [Full Text] [Related]  

  • 35. Prolongation of cardiac xenograft survival by depletion of complement.
    Leventhal JR; Dalmasso AP; Cromwell JW; Platt JL; Manivel CJ; Bolman RM; Matas AJ
    Transplantation; 1993 Apr; 55(4):857-65; discussion 865-6. PubMed ID: 8475561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascularised mouse-to-rat heart grafts: an unexpectedly difficult model of xenotransplantation.
    Sawyer GJ; Gustafsson K; Fabre JW
    Transplant Proc; 1995 Feb; 27(1):309. PubMed ID: 7879014
    [No Abstract]   [Full Text] [Related]  

  • 37. [Fine-structural analysis of hyper-acute rejection in cardiac xenotransplantation].
    Miyazaki K
    Hokkaido Igaku Zasshi; 2000 Sep; 75(5):347-56. PubMed ID: 11070795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged survival of cardiac xenografts between widely divergent species: bird to mammal.
    Braidley PC; Wallwork J; White DJ
    Transplant Proc; 1995 Feb; 27(1):307-8. PubMed ID: 7879013
    [No Abstract]   [Full Text] [Related]  

  • 39. Different immune effects on cardiac allografts and xenografts induced by neonatal intrathymic inoculation with allogeneic and xenogeneic antigens.
    Shen Z; Pelletier S; Mohiuddin M; Yokoyama H; Reiss GR; DiSesa VJ
    J Heart Lung Transplant; 1996 Oct; 15(10):1034-8. PubMed ID: 8913921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elucidation of rejection mechanisms using the splenocyte injection model in concordant xenotransplantation.
    Yasutomi M; Hayashi S; Ohtsuka S; Namii Y; Ito M; Uchida K; Yokoyama I; Takagi H
    Transplant Proc; 1995 Apr; 27(2):1583-4. PubMed ID: 7725417
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.